Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma

NCT07720284 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07720284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07720284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
July 16, 2026
Completion date
November 23, 2032
Enrollment
915 (estimated)
Sites
160

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk muscle invasive urothelial carcinoma